重组刺突蛋白新冠疫苗在炎症性肠病及移植受者中的免疫原性与安全性
结果显示免疫抑制组抗刺突IgG GMT从22,969升至66,639 EU/mL(2.9倍,p=0.001),健康对照组从54,812升至129,813 EU/mL(2.4倍,p<0.001),基线调整后第28天两组无显著差异,但6个月时免疫抑制组抗体衰减更快;疫苗耐受良好,无IBD flare或器官排斥。
要点
- NVX-CoV2601在免疫抑制患者中安全,未观察到IBD flare或器官排斥。
- 免疫抑制患者接种后抗体显著升高,第28天与健康对照无显著差异。
- 6个月时免疫抑制患者抗体衰减更快,提示需关注加强时机。
核心结论
- NVX-CoV2601在免疫抑制患者中安全且具有免疫原性,体液反应与健康对照相似,可作为该类人群的可行选择。
主要发现
- 免疫抑制组抗刺突IgG GMT从22,969升至66,639 EU/mL(2.9倍,p=0.001)。
- 健康对照组抗刺突IgG GMT从54,812升至129,813 EU/mL(2.4倍,p<0.001)。
- 基线调整后第28天两组间无显著差异。
- 6个月时免疫抑制组抗体衰减更快。
- 疫苗耐受良好,无IBD flare或器官排斥。
临床怎么用
- 对于已接种多剂新冠疫苗的免疫抑制患者,可考虑接种NVX-CoV2601加强针以提升体液免疫。
- 接种后6个月抗体衰减较快,需个体化评估加强免疫时机。
局限性
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunosuppressed individuals are at increased risk of coronavirus disease (COVID-19). Although mRNA vaccines have shown efficacy in these populations, data on protein-based vaccines remain limited. We evaluated the immunogenicity and safety of Novavax COVID-19 vaccine (NVX-CoV2601) in immunosuppressed patients. METHODS: This single-center, prospective ARMOR study included adults with inflammatory bowel disease (IBD) or solid organ transplant recipients receiving immunosuppressive therapy who had received ≥3 prior COVID-19 vaccine doses. Participants received one NVX-CoV2601 booster with follow-up at one and six months. The primary outcome was change in humoral immunogenicity from baseline to one month post-vaccination. RESULTS: Twenty-one immunosuppressed patients (18 IBD, 3 solid organ transplant recipients) were enrolled and compared with 57 age/sex-matched healthy controls. In ARMOR participants, anti-spike IgG GMT increased significantly post-immunization (22,969 to 66,639 EU/mL; 2.9-fold increase, p = 0.001). Healthy controls increased from 54,812 to 129,813 EU/mL (2.4-fold increase; p < 0.001). After baseline adjustment, no significant difference existed between groups at day 28. At 6 months, antibodies waned faster in immunosuppressed subjects. NVX-CoV2601 was well tolerated without IBD flares or organ rejection. CONCLUSION: NVX-CoV2601 was safe and immunogenic with similar humoral responses compared to healthy controls, making it a viable alternative for immunosuppressed patients.
引用
- Vattoth AL, Hayney MS, Forati AM, et al. Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient. Vaccine. 2026. PMID: 41547111. doi:10.1016/j.vaccine.2026.128208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。